Edoxaban GFR Cutoffs and Dosing
For patients with atrial fibrillation, edoxaban should NOT be used when CrCl <15 mL/min or >95 mL/min, with dose reduction to 30 mg daily required when CrCl is 15-50 mL/min. 1
Key GFR/CrCl Thresholds
Standard Dosing (60 mg once daily)
- CrCl >50 mL/min: Use edoxaban 60 mg once daily 1
- This is the standard dose for most patients with adequate renal function
Dose Reduction Required (30 mg once daily)
Reduce to 30 mg daily when CrCl is 15-50 mL/min 1
This corresponds to:
- Stage 4 CKD (CrCl 15-29 mL/min): Severely decreased renal function 2
- Stage 3b CKD (CrCl 30-44 mL/min): Moderately to severely decreased 2
- Upper Stage 3a CKD (CrCl 45-50 mL/min): Mildly to moderately decreased 2
Contraindications
Do NOT use edoxaban when:
- CrCl <15 mL/min (end-stage renal disease/dialysis) 2
- CrCl >95 mL/min (increased stroke risk due to reduced drug exposure) 1, 3
Clinical Reasoning
The 50% renal clearance of edoxaban necessitates careful dose adjustment 2. Unlike dabigatran (80% renal clearance) or apixaban (27% renal clearance), edoxaban has intermediate renal dependence, making the CrCl 15-50 mL/min threshold critical for dose reduction 2.
Important caveat: The upper limit restriction (CrCl >95 mL/min) is unique to edoxaban. Post-hoc analysis from ENGAGE AF-TIMI 48 showed decreased efficacy versus warfarin in patients with CrCl >95 mL/min, likely due to subtherapeutic drug levels from excessive renal clearance 3. Consider alternative DOACs in these patients.
Renal Function Monitoring
Use Cockcroft-Gault formula to calculate CrCl (not eGFR) for DOAC dosing decisions 2:
CrCl (mL/min) = [(140 - age) × weight in kg × 0.85 if female] / (72 × serum creatinine in mg/dL)
Monitor renal function at baseline and periodically, especially in:
- Elderly patients (≥75 years)
- Patients with baseline CKD
- Those with acute illness or dehydration
Special Populations
Severe CKD (CrCl 15-29 mL/min): While edoxaban 30 mg is approved in Europe for this population, evidence remains limited 2. Research suggests this dose may be safe with low rates of major bleeding and thromboembolism 4, but clinical judgment and close monitoring are essential.
Dialysis patients: Edoxaban is contraindicated. The routine use of any DOAC in dialysis-dependent patients lacks robust evidence 2.
Elderly ≥80 years: Post-hoc analysis supports edoxaban 30 mg daily even without traditional dose-reduction criteria, showing lower bleeding without increased ischemic events 5. However, follow FDA-approved dosing based on CrCl thresholds.